Potential of Magnetic Resonance Spectroscopy for Radiotherapy Planning
MRSI has the potential to provide metabolic evidence of tumor activity that may be an important guide for therapeutic decisions. The treatment planning process and treatment planning systems should therefore have the ability to incorporate both metabolic and anatomic data in order to determine appropriate target volumes. Many problems need to be addressed and much work needs to be done in order to determine the optimal way to incorporate indices of metabolic activity, especially in light of newer treatment techniques such as IMRT; however, it is the present author’s belief that strong consideration should be given to the incorporation of functional imaging into the treatment process for focal or boost treatments for brain and prostate tumors. Given the discrepancies that have been found between MRI and MRSI determinants of target volumes, the results of controlled dose escalation studies for malignant tumors of the brain that have used MRI-derived target volumes should also be reevaluated given the possibility that these volumes may have been suboptimally defined.
KeywordsRadiat Oncol Biol Phys Intensity Modulate Radiation Therapy Gamma Knife Magn Reson Image Recurrent Glioma
Unable to display preview. Download preview PDF.
- Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64:769–774Google Scholar
- Chuang C, Chan AA, Larson DL et al. (2004) Prognostic value of pre-Gamma Knife MR spectroscopic imaging for treatment strategy and clinical outcome. Int J Radiat Oncol Biol Phys (Abstract)Google Scholar
- McKnight TM, Vigneron DB, Love T et al. (2002b) Comparison of a Cho-NAA index with the MIB-1 proliferative index and cell density of tissue samples from grades II and III glioma. Proc 10th Scientific Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Honolulu, Hawaii, p 43Google Scholar
- Nelson SJ, McKnight TR, Henry RG (2002a) Characterization of untreated gliomas by magnetic resonance spectroscopic imaging. Neuroimag Clin North Am 12:599–613Google Scholar
- Pirzkall A (2005) Magnetic resonance spectroscopy and its use in brain tumor diagnosis and therapy. In: Black P, Loeffler JS (eds) Cancer of the nervous system, 2nd edn. Lippincott Williams and Wilkins, Philadelphia, pp 109–122Google Scholar
- Pirzkall A, Graves EE, Lau A et al. (2001b) Gamma knife (GK) radiosurgery (RS) for recurrent high-grade gliomas: What does magnetic resonance spectroscopy have to add? Fifth International Stereotactic Radiosurgery Society Congress (ISRS), Las Vegas, Nevada, p 44Google Scholar
- Sijens PE, Vecht CJ, Levendag PC et al. (1995) Hydrogen magnetic resonance spectroscopy follow-up after radiation therapy of human brain cancer. Unexpected inverse correlation between the changes in tumor choline level and post-gadolinium magnetic resonance imaging contrast. Invest Radiol 30:738–744PubMedGoogle Scholar
- Vigneron DB, Males R, Hricak H et al. (1998) Prostate cancer: correlation of 3D MRSI metabolite levels with histologic grade. RSNA, Chicago, p 181Google Scholar